Publications Database

Earle J. F. (2016)

An introduction to the psychopharmacology of children and adolescents with autism spectrum disorder.

Journal of Child and Adolescent Psychiatric Nursing

May, 29(2), pp. 62-71.

Read Abstract (New Window)

Eissa N. et al.

Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder.

Frontiers in Neuroscience

Read Full (New Window)

Ghuman J. K. et al. (2009)

Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit hyperactivity disorder symptoms in preschoolers with developmental disorders.

Journal of Child and Adolescent Psychopharmacology

19(4), pp. 329-339.

Read Abstract (New Window) Read Full (New Window)

Golubchik P. , Rapaport M. , Weizman A. (2017)

The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit-hyperactivity disorder.

International Clinical Psychopharmacology

September , 32(4), pp. 289-293.

Read Abstract (New Window)

Gringras P. (2000)

Practical paediatric psychopharmacological prescribing in autism: the potential and the pitfalls.

Autism

4(3), pp. 229-247

Read Abstract (New Window)

Handen B. L. , Johnson C. R. , Lubetsky M. J. (2000)

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.

Journal of Autism and Developmental Disorders

30(3), pp. 245-255

Read Abstract (New Window)

Hazell P. (2007)

Drug therapy for attention-deficit hyperactivity disorder-like symptoms in autistic disorder.

Journal of Paediatrics and Child Health

43(1), pp. 19-24

Read Abstract (New Window)

Hosenbocus S. , Chahal R. (2012)

A review of executive function deficits and pharmacological management in children and adolescents.

Journal of the Canadian Academy of Child and Adolescent Psychiatry

21(3), pp. 223-229.

Read Abstract (New Window) Read Full (New Window)

Hoshino Y. et al. (1977)

The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels.

Folia Psychiatrica et Neurologica Japonica

31(4), pp. 605-614

Read Abstract (New Window)

Jahromi L. B. et al. (2009)

Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.

Journal of Autism and Developmental Disorders

39(3), pp. 395-404

Read Abstract (New Window)

Jobski K. et al. (2016)

Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review.

Acta Psychiatrica Scandinavica

pp. 1-21.

Read Abstract (New Window)

Kim S. et al. (2017)

Dose-response effects of long-acting liquid methylphenidate in children with attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): a pilot study.

Journal of Autism and Developmental Disorders

August, 47(8), pp. 2307–2313.

Read Abstract (New Window)

Kirino E. (2014)

Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.

Clinical Medicine Insights: Pediatrics

May, 8 pp. 17-30.

Read Abstract (New Window) Read Full (New Window)

Leitner Y. (2014)

The co-occurrence of autism and attention deficit hyperactivity disorder in children: what do we know?

Frontiers in Human Neuroscience

8 268.

Read Abstract (New Window) Read Full (New Window)

Mahajan R. et al. (2012)

Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders.

Pediatrics

130 S125-138

Read Abstract (New Window) Read Full (New Window)

Mandell D. S. et al. (2008)

Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders.

Pediatrics

121(3), e441-e448

Read Abstract (New Window) Read Full (New Window)

Matson J. L. , Hess J. A. (2011)

Psychotropic drug efficacy and side effects for persons with autism spectrum disorders.

Research in Autism Spectrum Disorders

51

Read Abstract (New Window)

McCracken J. T. et al. (2014)

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.

Pharmacogenomics

14(3), pp. 295-302.

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. (2005)

Safety issues with drug therapies for autism spectrum disorders.

Journal of Clinical Psychiatry

66 pp. 32-37

Read Abstract (New Window)

Miller N. L. , Findling R. L. (2007)

Is methylphenidate a safe and effective treatment for ADHD-like symptoms in children with pervasive developmental disorders?

Expert Opinion on Pharmacotherapy

8(7), pp. 1025-1028

Read Abstract (New Window)